Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance

  • Brufsky A
  • Dickler M
118Citations
Citations of this article
294Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

© AlphaMed Press 2018 Advancements in molecular profiling and endocrine therapy (ET) have led to more focused clinical attention on precision medicine. These advances have expanded our understanding of breast cancer (BC) pathogenesis and hold promising implications for the future of therapy. The estrogen receptor-α is a predominant endocrine regulatory protein in the breast and in estrogen-induced BC. Successful targeting of proteins and genes within estrogen receptor (ER) nuclear and nonnuclear pathways remains a clinical goal. Several classes of antiestrogenic agents are available for patients with early, advanced, or metastatic BC, including selective ER modulators, aromatase inhibitors, and a selective ER degrader. Clinical development is focused upon characterizing the efficacy and tolerability of inhibitors that target the phosphatidylinositol 3 kinase (PI3K)/akt murine thymoma viral oncogene (AKT)/mammalian target of rapamycin inhibitor (mTOR) signaling pathway or the cyclin-dependent kinase 4/6 (CDK4/6) cell cycle pathway in women with hormone receptor-positive, human epidermal growth receptor 2-negative BC who have demonstrated disease recurrence or progression. De novo and acquired resistance remain a major challenge for women with BC receiving antiestrogenic therapy. Therefore, sequential combination of targeted ET is preferred in these patients, and the ever-increasing understanding of resistance mechanisms may better inform the selection of future therapy. This review describes the intricate roles of the PI3K/AKT/mTOR and CDK4/6 pathways in intracellular signaling and the use of endocrine and endocrine-based combination therapy in BC. Implications for Practice: The foundational strategy for treating hormone receptor-positive, human epidermal growth receptor 2-negative, advanced breast cancer includes the use of endocrine therapy either alone or in combination with targeted agents. The use of combination therapy aims to downregulate cell-signaling pathways with the intent of minimizing cellular “crosstalk,” which can otherwise result in continued tumorigenesis or progression through redundant pathways. This review provides the clinician with the molecular rationale and clinical evidence for these treatments and refers to evidence-based guidelines to inform the decision-making process.

References Powered by Scopus

Comprehensive molecular portraits of human breast tumours

9498Citations
N/AReaders
Get full text

Palbociclib and letrozole in advanced breast cancer

2169Citations
N/AReaders
Get full text

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study

1610Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Analysis of status and countermeasures of cancer incidence and mortality in China

257Citations
N/AReaders
Get full text

Breast cancer treatments: Updates and new challenges

212Citations
N/AReaders
Get full text

Mechanisms for estrogen receptor expression in human cancer

161Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Brufsky, A. M., & Dickler, M. N. (2018). Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. The Oncologist, 23(5), 528–539. https://doi.org/10.1634/theoncologist.2017-0423

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 79

74%

Researcher 18

17%

Professor / Associate Prof. 7

7%

Lecturer / Post doc 3

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 52

41%

Medicine and Dentistry 42

33%

Agricultural and Biological Sciences 17

13%

Pharmacology, Toxicology and Pharmaceut... 16

13%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free